Gilead is Global Leader in HIV/AIDS Funding, Says New Report

Learn more

More than 30 years since the first cases were reported, HIV/AIDS remains one of the world’s foremost health challenges, creating a continued need for philanthropic support. Our corporate giving program helps address the HIV epidemic on all fronts, including testing and linkage to care, enabling access to medicines, reducing disparities in the quality of healthcare and educating healthcare professionals on the latest advances in HIV therapies.

For example, AIDS Foundation East-West (AFEW) provides valuable testing and education resources to underserved populations living with HIV and hepatitis C virus (HCV) in countries of the former Soviet Union. “When most people think about diseases like HIV, they think about Africa. They don’t think about this region,” says Anke van Dam, executive director of AFEW. To change that, AFEW is using grants from Gilead to draw attention — and critically needed support — to the people living with HIV and HCV in the region. 

AFEW’s work is just one example of the more than a thousand grantees Gilead funds and partners with globally every year. A report titled “Restoring Urgency and Renewing Commitments,” released today by Funders Concerned About AIDS (FCAA), names Gilead as the top corporate funder and the No. 2 private philanthropic funder overall. Gilead gave $73.4 million in 2014, $46.6 million more than in 2013. In fact, Gilead helped spur an 8 percent increase in private philanthropic funding for HIV/AIDS in 2014, according to the report.

“We are very pleased to see that Gilead’s contributions have made a difference to organizations that do important work to help people infected with HIV/AIDS,” says Gregg Alton, Gilead’s executive vice president, Corporate and Medical Affairs. “The groups that we fund in HIV/AIDS, as well as in the other therapeutic areas in which we do work, have a critical impact on the lives of millions of people around the world.”

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.